Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact

Evolus Reports First Quarter 2021 Results and Provides Business Update

Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA (Jeuveau) to decrease the appearance of glabellar lines (also known as frown lines between the eyes). The two Phase 2 studies demonstrate that prolonged use of Jeuveau is safe and effective with repeat treatments.

Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Evolus (EOLS) Might Surprise This Earnings Season

Allstate

Booking Hlds

CyberArk Software

Hilton Worldwide Holdings

Chemours

Kratos Defense & Security Solutions

Ultragenyx Pharmaceutical

With the trading day about halfway over, the broad markets were somewhat mixed. The Dow Jones industrial average and S&P 500 each posted a handy gain, while the Nasdaq was barely in the red.

Allstate, Booking, CyberArk, Hilton and More Thursday Afternoon Analyst Calls

NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2021 financial results and provide a business update on Wednesday, May 12, 2021, after the close of the U.S. financial markets.

Evolus to Report First Quarter 2021 Results and Provide Business Update

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Few are smiling about the company's upcoming share issue.

Why Evolus Stock Dived by Almost 19% Today

NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering price of $9.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be $85.5 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about April 26, 2021, subject to satisfaction of customary closing conditions. All the shares in the offering are being sold by Evolus.

Evolus Announces Pricing of Public Offering of Common Stock

NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Evolus.

Evolus Announces Proposed Public Offering of Common Stock

Evolus' (EOLS) CEO David Moatazedi on Q4 2020 Results - Earnings Call Transcript

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q4 Loss, Lags Revenue Estimates

Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ®

Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

Evolus Inc (NASDAQ: EOLS) has announced that its strategic partner Daewoong Pharmaceutical Co. Ltd will pay Evolus $25.5 million in cash and eliminate $10.5 million of current and potential future milestone payments. Additionally, Daewoong will convert its debt into Evolus common shares, further reducing $40.5 million in convertible debt.

Daewoong Pharmaceutical Injects More Liquidity In Evolus

NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and year end 2020 financial results and provide a business update conference call and live audio webcast on Wednesday, March 24, 2021.

Evolus to Report Fourth Quarter and Year End 2020 Results and Provide Business Update

Pro Forma Cash Position of $57 Million at December 31, 2020 1

Evolus Strengthens Balance Sheet Through a $25.5 Million Cash Infusion and Elimination of $127.4 Million of Debt and Milestone Payments

NEWPORT BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two upcoming virtual investor conferences.

Evolus to Participate in Two Upcoming Investor Conferences

Is a Surprise Coming for Evolus (EOLS) This Earnings Season?

NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief Marketing Officer effective today.

Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer

Abercrombie & Fitch

Mattel

Western Digital

Allakos Inc

Emergent BioSolutions

Generation Bio

Schnitzer Steel Industries Inc

Thomson Reuters

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls

Evolus (EOLS) stock was on the rise Friday following news that it's no longer dealing with lawsuits from AbbVie (ABBV) and Medytox. The post EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today appeared first on InvestorPlace.

EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today

NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference.

Evolus to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

The stock price of Evolus Inc (NASDAQ: EOLS) is trading at over 60% today. This is why it happened.

EOL Stock Price Increases Over 60%: Why It Happened

Novavax

Vaccinex Inc

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechnology company that develops vaccines.

Why Novavax, Vaccinex, Evolus Are Trading Higher Today

AbbVie

Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox

NORTH CHICAGO, Ill. and NEWPORT BEACH, Calif. and SEOUL, Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case...

News for Evolus Stock (EOLS)